Pluripotent cells are a transient population present in the early mammalian embryo dependent on transcription factors, such as OCT4 and NANOG, which maintain pluripotency while simultaneously suppressing lineage specification. Interestingly, these factors are not exclusive to uncommitted cells, but are also expressed during early phases of differentiation. However, their role in the transition from pluripotency to lineage specification is largely unknown. Using genetic models for controlled Oct4 or Nanog expression during postimplantation stages, we found that pluripotency factors play a dual role in regulating key lineage specifiers, initially repressing their expression and later being required for their proper activation. We show that the HoxB cluster is coordinately regulated in this way by OCT4 binding sites located at the 3' end of the cluster. Our results show that core pluripotency factors are not limited to maintaining the pre-committed epiblast, but are also necessary for the proper deployment of subsequent developmental programs. Dual regulation of Hox genes by pluripotency factors Lopez-Jimenez et al. 3
INTRODUCTION
Pluripotency, the ability of a cell to give raise to derivatives of all embryonic germ layers, occurs in cultured embryonic stem cells and for a brief period during development of the mammalian embryo. A small group of transcription factors, most importantly OCT4, NANOG and SOX2, controls this state both in vivo and in culture by regulating a large battery of downstream target genes (1, 2) . During preimplantation stages of mammalian embryos, these factors are expressed in the epiblast of the blastocyst, which shares various molecular features with embryonic stem (ES) cells, among them the expression of the core pluripotency factors. It is assumed that progression from pluripotency towards differentiation requires the downregulation of the core pluripotency factors that would lead to the expression of lineage determination genes and turning on of specific developmental pathways.
However, the expression of pluripotency factors beyond the blastocyst stage suggests roles not directly related to pluripotency maintenance (3) . Oct4 (official gene symbol Pou5f1) is continuously expressed up to embryonic day (E) 8.5, initially throughout the epiblast and subsequently showing progressive restriction to the posterior part of the embryo (4, 5) . Nanog is re-expressed at E5.5 but only in the posterior-proximal region where it has been shown to control development of the primordial germ cells (6, 7) , and is turned off by E7.5 (8) . Loss-of-function approaches to investigating the role of Oct4 and Nanog at these stages have proved difficult because preimplantation lethality precludes analysis of later phenotypes (9, 10) . To overcome early lethality, conditional Oct4 mutants have been analyzed at post-implantation. However, loss of Oct4 at these stages leads to tissue disorganization and proliferation defects at gastrulation, what could obscure potential lineage-specific defects (11, 12) . Therefore, we still lack a complete understanding of the roles of pluripotency factors during development, as well as how pluripotency and differentiation programs are coordinated in the embryo. 
RESULTS

Stage-dependent regulation of developmental genes by pluripotency factors
To overcome the limitations or early embryonic lethality and disruption of gastrulation associated with the loss of function of core pluripotency factors, we used doxycycline (dox)-inducible transgenic mouse models providing controlled Oct4 or Nanog expression in post-implantation embryos (13) (14) (15) . We chose two different time windows for induction of Oct4 and Nanog: from E4.5 to E7.5 and from E6.5 to E9.5 ( Fig. 1A) , thus maintaining expression beyond the point when endogenous gene activity is turned off. Robust expression of both transgenes was obtained at E7.5 and E9.5 (Fig. S1A) , with higher levels in neural tube and mesoderm ( Fig. S1B ).
Nevertheless, expression levels of Oct4 or Nanog in treated embryos were comparable or even lower to those in E14 or R1 (16) ES cells ( Fig. S1C ). We analyzed the transcriptomes of embryos from untreated and dox-treated females and compared gene-expression changes between stages and models.
More than 50% of genes differentially expressed upon Oct4 expression up to E7.5 also changed when Nanog was induced in the same time window (Fig. S1D ), and included major developmental regulators. However, this proportion halved when we compared changes occurring in E9.5 embryos (24%). Similarly, 23% of genes deregulated by Oct4 at E7.5 also changed at E9.5. As for Nanog, 36% of genes changing at E7.5 were shared with Oct4, 16% at E9.5, and only 14% were common at both stages in Nanog-expressing embryos (Fig. S1D ). The observed degree of overlap between changes induced by Oct4 and Nanog may appear small, in light of their many common target genes in embryonic stem (ES) cells (17) ; however, this finding is in line with the outcome of overexpressing or knocking-down these factors in culture (18, 19) . Core factors of the pluripotency gene regularly network are known to activate each other's expression (2, 17) . We observed positive cross-regulation of Oct4 and Nanog at E7.5, but not at E9.5 (Fig. S1A ). Furthermore, we did not observe upregulation of other pluripotency factors, such as Sox2, upon Oct4 or Nanog expression. Therefore, there is not an overall activation of the embryonic pluripotency program in the gastrulating embryo driven by these factors.
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Lopez-Jimenez et al. 5 We performed unsupervised hierarchical clustering of the data (20) using genes that were differentially expressed in at least one condition (4090 genes). Most of the resulting clusters ( Fig. 1B) show a stronger tendency for upregulation or downregulation in only one condition (e.g. clusters #1-5; Fig. S2A ), confirming the largely independent and stage-specific effects of Oct4 and Nanog expression.
Functional annotation showed that most clusters were enriched for genes involved in development and transcription, with some exceptions such as cluster #5, which is enriched for cell-cycle genes, and cluster #7, which includes genes involved in lipid metabolism ( Fig. S2B ).
To gain insight into functional targets among the de-regulated genes, we checked for the presence of OCT4 or NANOG binding sites in their vicinity by examining published ChIP-seq data in ES cells (21, 22) . We assessed for binding near genes from each cluster compared to genes differentially expressed in at least one condition (Fig. 1C) . Surprisingly, only three clusters (#6, #8 and #10) showed consistent enrichment for genes located near OCT4 and NANOG sites (Fig. 1C ).
Moreover, these clusters showed an intriguing pattern in response to Oct4 and Nanog: clusters #6 and #10 were upregulated by both Oct4 and Nanog at E7.5 and downregulated at E9.5, whereas cluster #8 showed the opposite behavior (Fig. S2A ).
The three clusters are enriched for developmental regulators (Fig. S2B) ; however, whereas clusters #6 and #10 include early epiblast genes (e.g. Chordin, Dnmt3a/3b, Eomes, Eras, Esrrb, Etv5, Fgf4/5, Foxa2, Gsc, Lefty2, Mesp1/2, Nodal, Otx2, Snai1, Tdgf1, Zic5), cluster #8 includes multiple lineage specification genes (e.g. Cdx1/2/4, Dlx5/6, Fgf3, Gata5/6, Gbx2, Gli1/2/3, Hnf1b, Hox genes, Irx3/4/5, Meis1/2/3, Msx1/2, Pitx1/2, Tbx genes, and Wnt3a/5a/5b/6) ( Fig. 1D ).
Widespread regulation of Hox genes by pluripotency factors
The large number of Hox genes in this last group (18 genes) prompted us to examine the response of all 39 Hox genes to Oct4 and Nanog ( Fig. 2A ). Nanog has a mild effect on Hox cluster expression ( Fig. 2A ), mostly downregulating their expression at early stages (14 genes downregulated and 3 upregulated at E7.5, and 5 when expressed up to E9.5 ( Fig. 2A ). It is noteworthy that in this case no Hox gene was upregulated at E7.5 or downregulated at E9.5. Oct4 affects expression of Hox genes from all four clusters (HoxA-D), but excluding most of the posterior Hox genes from paralog groups 10-13. Interestingly, recent work has shown that Oct4 delays the activation of posterior Hox genes in trunk progenitors at later embryonic stages (23) , suggesting that Oct4 could have opposite roles in the regulation of anterior and posterior Hox genes during development (24) .
These results strongly suggest that endogenous Oct4 might be regulating Hox genes during post-implantation development. To address if Oct4 and Hox genes overlap in the embryo we analyzed published single-cell expression data in E6.5-E7.75 embryos (25) finding that the majority of cells expressing Hox genes co-express Oct4 (Fig. S3A ). This does not rule out the possibility that expression of Hox genes is only occurring in cells that might be turning off Oct4, showing low levels of its expression, as a prerequisite for proper lineage commitment. However, Hox expressing cells from E6.5-E7.75 embryos (25) express Oct4 in an equivalent range to that of all Oct4 positive cells from the same stages ( Fig. S3B ). Together, this evidence is compatible with a direct role of Oct4 in the regulation of Hox clusters.
To determine when the switch from Hox gene repression to activation takes place, we induced Oct4 for 1.5-day periods between E5.5 and E8.0, harvesting embryos between E7.0 and E9.5 ( Fig. 2B ). We examined the expression of Hoxa1 and three HoxB cluster genes (Hoxb1, Hoxb4 and Hoxb9) by RT-qPCR using genotypematched embryos from non-dox-treated females as controls. Consistent with the transcriptomic data, we observed a switch from repression to activation. However, the switch occurred earlier for Hoxa1 and Hoxb1 than for Hoxb4 and Hoxb9 (Fig.   2C ), resembling the collinear activation of the clusters in the early embryo (26, 27) .
We next examined Oct4-induced changes to HoxB gene expression patterns by in situ hybridization of E7.0-7.5 and E9.5 embryos exposed to dox for 3 days. At E7.0-7.5, expression of Hoxb1 and Hoxb4 was downregulated in the posterior of the 7 embryo, as predicted from the transcriptomic analysis, and at E9.5 we observed gain of expression for HoxB genes in several domains of the embryo (Fig. 2D ). Hoxb1 was the most notably affected, with a shift along the anterior-posterior axis ( Fig. S4A , arrowhead) together with upregulation or persistence of expression in presumptive rhombomere 6 territory ( Fig. S4A , asterisk). Expression of Hoxb4 conserved its anterior limit of expression ( Fig. S4A, arrowhead) , but showed an irregular and patchy pattern in the neural tube ( Fig. S4A, bracket) . As for Hoxb9, the anterior limit of expression in the neural tube ( Fig. S4A , white arrowhead) shifted anteriorly in comparison with the anterior limit in the paraxial mesoderm ( Fig. S4A , black arrowhead). Most strikingly, all three genes examined showed patches of expression in the anterior neural tube ( On the other hand, Nanog caused no obvious changes in Hox gene expression in E9.5 embryos except for an anterior expansion of the Hoxb1 domain in the neural tube, similar to what we observed for Oct4 ( Fig. S4F ).
Global control of the HoxB cluster by OCT4
To investigate how pluripotency factors regulate Hox genes, we examined previously published ChIP-seq binding profiles of OCT4 and NANOG in mouse ES cells (22, 29) . We detected almost no binding within the clusters, with the exception of HoxD, but observed prominent peaks at the anterior ends of the clusters ( Fig. 3A and Fig.   S5A ). For example, in the HoxB cluster, both OCT4 and NANOG bind proximally to the Hoxb1 promoter (P-site) and to a distal region (D-site) approximately 9 kb downstream of the transcriptional start site (Fig. 3A ). These sites have been shown to bind OCT4 during ES cell differentiation (30) , and are shared sites of OCT4 8 binding between ES cells and epiblast-like cells (EpiLC) in the transition from naïve to primed pluripotency (16) .
We confirmed these sites were occupied by OCT4 in ES cells by ChIP-qPCR ( Fig.   3B ), using a region from the Nanog promoter, previously shown to be bound by OCT4 (29, 31) , as a positive control and other unrelated genomic regions as negative controls (Fig. S5B ). ChIP in E9.5 embryos showed no binding, but after dox administration we observed binding at both the P-and D-sites ( Fig. 3B ), demonstrating that these sites are occupied by OCT4 upon induction of its expression.
The response of multiple Hox genes to Oct4 we observe in the RNAseq dataset and in whole mounts in situs suggests the existence of global mechanisms of Hox cluster regulation by pluripotency factors. To address if these regions could be acting as common regulatory elements for the cluster, we examined their interaction profile by circular chromatin conformation capture followed by high-throughput sequencing (4C-seq) (32, 33) . We designed viewpoints for both the P-and D-sites and carried out 4C-seq in mouse ES cells, where OCT4 is present and HoxB genes are not expressed, and in dox treated and untreated E9.5 Oct4 tg embryos ( Fig. 3C ).
Normalized reads were used to fit a distance decreasing monotone function, to take into account that nearby fragments will randomly interact more frequently, and contacts that deviated significantly from the normal distribution were identified.
The chromatin structure surrounding the anterior end of the HoxB cluster is relatively stable independently of its expression ( Fig. 3C ), as shown for other viewpoints in the cluster (32) . Interaction occurs on both sides of the viewpoints: towards the HoxB cluster itself, with a strong limit near Hoxb13; and outside of the cluster towards the telomeric region ( Fig. 3C ). However, interactions are differently distributed around the viewpoint in ES cells and embryos. In ES cells, there are more interactions towards the Hoxb13 region, possibly reflecting the closed conformation of the cluster mediated by poised promoters (34) , whereas in E9.5 embryos interactions increase towards the telomeric gene desert defined by Skap1 (Fig. 3C ), whose expression at E7.0-E7.75 is limited to embryonic blood progenitors (25) . This difference in Dual regulation of Hox genes by pluripotency factors Lopez-Jimenez et al. 9 interactions might reflect the active state of the HoxB cluster in the embryo, where distal regulatory elements located in this region (35) are recruited to define its correct expression, as is also the case for the HoxA cluster (36) . Our observations are also in line with recent results that show that the HoxA and HoxD clusters are organized in compact domains in ES cells that open up during differentiation (37) . Interestingly, when Oct4 is induced in E9.5 embryos, novel contacts are established from both the P and D sites towards the cluster (asterisks, Fig. 3C ) accompanied by a reduction in the interactions with the Hoxb13 domain (dashed boxes, Fig. 3C ). We can conclude that these regions at the telomeric end of the HoxB cluster, which are bound by pluripotency-factors, establish intra-cluster interactions in active or inactive states.
Furthermore, the presence of OCT4 in E9.5 embryos leads to a reorganization of the local architecture of the HoxB cluster.
OCT4 is necessary for proper activation of the HoxB cluster
We next wished to explore the effect of the lack of Oct4 on the expression of Hox genes. To do so, we analyzed expression of HoxB genes in ES cells depleted of Oct4. For this, we used the ZHBTc4 ES cell line that has both copies of endogenous Oct4 deleted and harbors a tetracycline (tet) dependent Oct4 transgene, where addition of the drug leads to the quick downregulation of Oct4 (38) . We treated ZHBTc4 ES cells for up to 72 hours (3 days) with tet in 2i culture conditions (39) , in order to minimize differentiation of the cells, leading to complete silencing of Oct4 after the first 24 hours (Fig. S6A ). This was accompanied by a more gradual downregulation of Nanog, and a sharp upregulation of Cdx2 as previously described (38, 40) after the first day of tet treatment, that declined on following days ( Fig. S6A) possibly as the result of selection against partially differentiated cells in 2i conditions. Genes from the HoxB cluster showed different behaviors in response to loss of Oct4.
While Hoxb1 was downregulated in the absence of Oct4 at all days, Hoxb4 showed initial upregulation at day 1 but downregulation by day 3. On the other hand, Hoxb9 was upregulated throughout the 3-day culture (Fig. 4A ). Therefore, Oct4 is 10 necessary for basal activation of 3' genes, while needed to repress expression of further 5' HoxB genes.
Deletion of the distal OCT4 site disrupts the pattern of HoxB expression during differentiation.
To complement these observations, we decided to test the necessity of the OCT4 bound regions described above in the regulation of the HoxB cluster by deletion in ES cells by CRISPR/Cas9 mediated genome editing (41) . We examined the genomic regions covered by ChIP-seq peaks, finding that the proximal site (P) contains one consensus OCT4 binding site, while the distal site (D) at least two ( Fig. S6B ). In the case of the P-site, this consensus lies within the previously described proximal showed a similar trend for each of the Hox genes examined independently of the differentiation protocol, and a comparable behavior in the two independent clones ( Fig. 4B ). Hoxb1 is initially expressed at higher levels in deleted cells, but is downregulated as compared to controls at later stages of differentiation. Hoxb4 also shows initial upregulation, but no significant changes at later time points. Finally, Hoxb9 is consistently activated in deleted cell lines throughout the differentiation window analyzed (Fig. 4B) , as also occurs when Oct4 is depleted from ES cells (Fig.   4A ).
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To analyze the effect of the deletion in vivo, we used the HoxB D-site Δ/Δ ES cells to generate mouse lines. Homozygous mice survive to term, what did not come as a surprise, as deletion of the entire HoxB cluster in homozygosity does not cause embryonic lethality (47) . We examined the expression of Hoxb1 and Hoxb4 at E7.5, a time when anterior HoxB genes and Oct4 are still co-expressed (Fig. S3A, B ). RT-qPCR showed down-regulation of Hoxb1 and upregulation of Hoxb4 in deleted embryos (Fig. 4C ). This further confirms the different roles of Oct4 at this stage, when it would be necessary for proper levels of express info Hoxb1 but still lowering
Hoxb4.
Whole mount in situ hybridization at the early head-fold stage showed no clear changes in Hoxb1, but an expansion of the expression in the primitive streak region at the posterior part of the embryo of Hoxb4 (white dashed line, Fig. 4D ). We also examined expression of HoxB genes in E9.5 embryos from the HoxB D-site Δ/Δ line, and did not observe mayor changes except for overall lower levels of Hoxb4 expression ( Fig. S6D ). Therefore, these results suggest that at early stages of expression, OCT4 is necessary to fine-tune expression of HoxB genes in their endogenous domains.
DISCUSSION
It is generally assumed that pluripotency factors act to restrict lineage decisions before gastrulation. However, Oct4 has been shown to participate in several later developmental decisions, including primitive endoderm development (48) , lineage priming (30, 49, 50) , primitive streak proliferation (12) , and the regulation of trunk length (23) . Furthermore, recent results have shown how the lack of Oct4 in early gastrulating embryos results in a blockade of epithelial-to-mesenchymal transition in the posterior epiblast, thus disrupting proper axis formation (11) . Both single-cell RNA-seq data and in situ detection show that Oct4 and Hox genes are co-expressed in cells of the gastrulating embryo, from the onset of Hox gene expression and up to E8.5 (4, 5, 25) . We propose that at these early stages, Oct4 plays a dual role, first 12 maintaining Hox genes silent before lineage commitment, and later being required for their proper activation. This behavior is specific for Oct4, as in the case of Nanog we only observe initial repression of Hox genes, which agrees with the recent description of the mutual cross-repression of Nanog and Hoxa1 to differentially regulate a common set of downstream target genes involved in early phases of lineage commitment (51) . 
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MATERIALS AND METHODS
Animal models
Double-homozygote transgenic males of the Oct4/rtTA (R26-M2rtTA;Col1a1-tetO-Oct4) (14) or Nanog/rtTA (R26-M2rtTA;Col1a1-tetO-Nanog) (15) mouse lines were mated with CD1 females, which were treated with 0.2 or 1 mg/ml dox in the drinking water to induce the Oct4 or Nanog transgene respectively in embryos. For Oct4 transgene induction in E7.5 embryos to be used for in situ hybridazation, a single 100μl intraperitoneal injection of 25µg/µl doxycycline was administered to pregnant females at E5.5, followed by 0.5 mg/ml dox administration in drinking water. Non treated mice of the same genotype were used as controls. Mouse lines deleted for the Oct4 distal site adjacent to Hoxb1 were generated by blastocyst injection of mutated ES cells (see below) following standard procedures (52) .
RNA-seq
RNA-seq was performed with three biological replicates, each consisting of pools of 8-12 E7.5 embryos or three E9.5 embryos obtained from untreated (controls) or doxycycline-treated double heterozygous embryos. Equally, three biological replicates of E14 ES cells were used for RNA-seq. Single-end sequencing was performed by the CNIC Genomics Unit using a GAIIx sequencer. Adapters were removed with Cutadapt v1.14 and sequences were mapped and quantified using RSEM v1.2.20 to the transcriptome set from Mouse Genome Reference NCBIM37 and Ensembl Gene Build version 67. Differentially expressed genes between groups were identified using the limma bioconductor package. Only p-values < 0.05 adjusted through Benjamini-Hochberg procedure were considered as significant.
Clustering analysis was conducted for all genes differentially expressed between the induced and control conditions for any of the four conditions. Overrepresented biological categories were identified using DAVID v6.8 (53) . Lists of genes located close to OCT4 and NANOG binding sites were generated from published ChIP-seq datasets (21, 22) . 
RT-qPCR assays
Total RNA from single embryos from E8.0 onwards, embryo pools up to E7.5, or ES cells directly lysed in their wells, was extracted with RNeasy kit (Qiagen) and digested with DNAse I (Qiagen) to remove genomic DNA. 0.5-1.0 μg of total RNA was reverse transcribed using Quantitech Reverse kit (Applied Biosystems).
Quantitative PCR was performed with SYBR green Master Mix (Applied Biosystems)
on an AB 7900-Fast-384 machine. Expression values were normalized to the expression of Actb and Ywhaz (whose expression as measured in our RNA-seq data did not change upon Oct4 or Nanog induction) using the comparative CT method (54) and standard deviations were calculated and plotted using Prism 7.0 software (GraphPad). All assays were performed in triplicate.
In situ hybridization
In situ hybridization in whole mount embryos or sections was performed using digoxigenin-labeled probes as described (55) . Probes for Hoxb1, Hoxb4, Hoxb9 and Otx2 were generated by PCR, and the probe for Oct4 was kindly provided by Tristan Rodriguez (Imperial College London). Early embryos were staged according to Forlani et al (2003) .
4C-seq
4C was performed as previously described (32, 33) on two replicates of pools of 60-70 E9.5 embryos or 1-2x10 6 G4 ES cells. Samples were crosslinked with 2% PFA, frozen in liquid nitrogen and stored at -80º. Chromatin was digested with DpnII (New window was used to fit a distance decreasing monotone function and Z-scores were calculated from its residuals using a modified version of FourCSeq (56) . Significant contacts were considered in cases where the z-score was >2 in both replicates and deviated significantly (adjusted p value <0.05) from its normal cumulative distribution in at least one of the replicates.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using 10 9.5 embryos or 1x seconds ON 30 seconds OFF for 30 minutes). Immunoprecipitations was carried out using rabbit polyclonal anti-OCT4 antibody (Abcam; ab19857), and anti-Rabbit IgG polyclonal antibody (Abcam; ab171870) was used as negative control. Enrichment was measured by qPCR. A fragment from the Nanog promoter was used as a positive control (29, 31) , and genomic fragments from the loci of Anks1b, Smg6 and Tiam1 as negative controls (57), after checking they did not contain OCT4 bound peaks (29) .
ES culture, cell editing and differentiation
ZHBTc4 cells were maintained in culture on 0.1% gelatin (sigma) using corning p24 plates with cell bind surface. Medium contained inactivated fetal calf serum (Hyclon), LIF (produced in-house) and 2i (PD0325901 and CHIR99021 Sigma). After one day in culture cells were treated with 1ug/ml tetracycline (Sigma) to turn of Oct4. Cells were collected from day 1 to 3 from the start of treatment. CRISPR/Cas9-mediated deletions in G4 mouse ES cells were generated using two guide RNAs together with a plasmid for Cas9. Cells were transfected, selected by sorting, and replated. G4 ES cells (control), clone #30 and clone #57 were differentiated as described (45, 46) in monolayer using corning p24 plates with cell bind surface and with 0.1% gelatin (Sigma) added 30 min before passing. Cells were grown in N2B27 media supplemented with 10 ng/ml bFgf (R&D) for 3 days (d1-d3) and then were transferred into different media depending on the differentiation process. To induce hindbrain identity 10 nM RA (Sigma) was added from D3-D5. Spinal cord identity was induced by the addition of 5 µM CHIR99021 (Sigma) from D2 to D3 followed by 100 nM RA from D3-D5. To induce mesodermal differentiation the cells were treated with CHIR990215uM from D2-D5. Cells were collected at each time point by adding lysis buffer directly to the wells. Fig. S1 . Characterization of the Oct4 tg or Nanog tg mouse models. Table S1 . Differentially expressed genes upon doxycycline treatment of Oct4 tg or Nanog tg inducible models in E4.5 to E7.5 and E6.5 to E9.5 time windows. Table S2 . Clusters generated by unsupervised hierarchical clustering of genes differentially expressed in at least one condition. Table S3 . Gene Ontology analysis of clusters generated by unsupervised hierarchical clustering of genes differentially expressed in at least one condition. Table S4 . Primers and oligonucleotides used in this study. 
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